Τόμος 6 (1988) – Τεύχος 1 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 6 (1988) – Issue 1 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

6: 17-33 (1988)

PHARMAKON-Press: Epitheorese Klin. Farmakol. Farmakokinet.

6: 17-33 (1988)

Observations from a considerable number of uncontrolled and controlled trials indicate that treatment with immunosuppressive or immunostimulatory agents can alter the clinical course of M.S. Better progress has been made in the field of immunosuppressive therapy. Much effort is concentrated on the detection of a multiple sclerosis susceptibility gene. Should this research be successful then antibodies directed against distinct MHC products may suppress immune responses which produce demyelination. Both immunosuppresive and immunostimulatory treatments have been found to be most effective in the early stages of M.S. It is therefore recommended that new studies should distinguish patients in early stages from those in advanced. Finally, since ΗLΑ antigens seems to influence sensitivity to therapeutic agents the stratification of patients according to their HLA type may further increase treatment efficacy.

1. Firth, D.: The case of Augustus D’Este. Cambridge university Press, 1948
2. Mttyus, A. and Veres, Ε.: M.S. in childhood: long term katamnestic investigation. Acre Peed, Hung. 26: 193 (1985)
3. Noseworthy, J., Paiy, D., Wonnacott, T., Feasby, T., Ebers, G.: Μ.S after age 50. Neurology (N.Y.) 33.’ 1537 (1983)
4. Hammann, K.P. and Hopf, H.C.: Monocytes constitute the only peripheral blood cell ρορulatiοn showing an increased burst activity in M.S patients. Intern. Arch. Allergy and Appl. immuiwi. (Switz.) 81: 230 (1986)
5. Hauser, S.L.: CSF cells in M.S. Neurology 33: 575 (1983)